Skip to content
Home/Companies/Biotech/Neogene Therapeutics

Neogene Therapeutics

Biotech·France·Exited 2023·Held 3yr
Entry
2020
Hold
3yr
Exit
2023

Who owns Neogene Therapeutics?

Neogene Therapeutics is a French Biotech company, now owned by AstraZeneca, which acquired it in 2023 from Jeito Capital.

Hand-verified · updated 2026-09-30

Open JSON · CC-BY
Jeito Capital
Investor
Jeito Capital
Jeito I · 2021 · VC

Key facts

HQFrance
SectorBiotech
Exit Type
Trade Sale
Buyer
AstraZeneca
Exit Year
2023

More from Jeito I

Other portfolio companies in the same fund.

Corteria Pharmaceuticals
Corteria Pharmaceuticals
Active
BiotechFrance· 2023
Noema Pharma
Noema Pharma
Active
BiotechSwitzerland· 2023
Advesya
Advesya
Active
BiotechSpain· 2022
CatalYm
CatalYm
Active
BiotechGermany· 2022
CDR-Life
CDR-Life
Active
BiotechSwitzerland· 2022
EyeBio
Exited 2024
BiotechUS· 2022
to Merck

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns Neogene Therapeutics?

Neogene Therapeutics is now owned by AstraZeneca, which acquired it in 2023 from Jeito Capital.

When did AstraZeneca acquire Neogene Therapeutics?

AstraZeneca acquired Neogene Therapeutics in 2023, buying from Jeito Capital.

Who did Neogene Therapeutics sell to?

Jeito Capital sold Neogene Therapeutics to AstraZeneca in 2023 (Trade Sale).

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue